Serum alpha-hydroxybutyrate dehydrogenase levels in children with sickle cell disease

The American Journal of Pediatric Hematology/Oncology
|January 1, 1981
PubMed

Insights

Serum alpha-hydroxybutyrate dehydrogenase (alpha-HBDH) levels help distinguish sickle cell disease (SCD) crises from infections. Elevated alpha-HBDH indicates a crisis, while normal levels suggest infection in SCD patients.

Area of Science:

  • Biochemistry
  • Hematology
  • Pediatrics

Background:

  • Sickle cell disease (SCD) is a genetic blood disorder with significant health complications.
  • Differentiating between vaso-occlusive crises and infections is crucial for effective SCD management.
  • Serum biomarkers can aid in diagnosing acute complications in SCD.

Purpose of the Study:

  • To investigate serum alpha-hydroxybutyrate dehydrogenase (alpha-HBDH) levels in children with sickle cell disease (SCD).
  • To determine if alpha-HBDH levels can differentiate between steady state, vaso-occlusive crisis, and infection in SCD patients.

Main Methods:

  • Serum alpha-HBDH levels were measured in 28 children with homozygous SCD during steady state, crisis, and postcrisis.
  • Alpha-HBDH levels were also assessed in 20 patients with infection.
  • Levels were compared to control values and between different clinical states.

Main Results:

  • Children with SCD in the steady state showed significantly elevated alpha-HBDH levels compared to controls.
  • A further significant increase in alpha-HBDH levels was observed during vaso-occlusive crises.
  • Patients with infection did not exhibit a significant increase in serum alpha-HBDH levels.

Conclusions:

  • Serum alpha-HBDH levels are significantly elevated in SCD patients during steady state and crisis.
  • Elevated alpha-HBDH levels can effectively differentiate vaso-occlusive crises from infections in SCD.
  • This biomarker aids in accurate diagnosis and management of SCD complications.